. 2022 Apr 19;73(Suppl 1):1–44. doi: 10.1007/s00105-022-04977-8

Table 3.

Summary of data for the vein drugs approved in Germany (from [103])

Active principle	Dose	Data from robust RCTs^a		Supporting data^b
Active principle	Dose	Significant reduction of oedema	Significant improvement in symptoms	Supporting data^b
Standardised red vine leaf extract^c	Once per day 360–720 mg	Kiesewetter et al. (2000) [120]	Kiesewetter et al. (2000) [120]	Kalus et al. (2004) [123]
Standardised red vine leaf extract^c	Once per day 360–720 mg	Rabe et al. (2011) [121]	Rabe et al. (2011) [121]	Kalus et al. (2004) [123]
Standardised horse chestnut extract^d	Twice per day 50 mg (aescin)	Diehm et al. (1996) [74]	n. i.	Neiss et al. (1976) [124]
Standardised horse chestnut extract^d	Twice per day 50 mg (aescin)	Diehm et al. (1996) [74]	n. i.	Cloarec (1992) [117]
Oxerutin	Twice per day 500 mg	Unkauf et al. (1996)^e [112]	n. s.^e	Cloarec et al. (1996) [125]
		Diebschlag et al. (1994) [122]	Diebschlag et al. (1994) [122]	Grossmann et al. (1997) [118]
		Diebschlag et al. (1994) [122]	Diebschlag et al. (1994) [122]	Petruzzellis et al. (2002) [114]

n. i. not investigated, n. s. not significant, RCT randomised controlled trial

^aCarried out in accordance with the guidelines of the German Society of Phlebology (DGP). Vanscheidt et al. (2000) [119]

^bSmall and/or short RCTs, inadequate measurement of the reduction of oedemas, etc.

^cProportion of active principle red vine leaf extract (RVLE); 4–6:1

^dProportion of active principle horse chestnut extract (HCSE); 4.5–5.5:1

^eCompression therapy in both treatment groups